Repaglinide
رپاگلینید
🍽️ Alimentary Tract And MetabolismGlinide (insulin secretagogue)
Market / country: 🇺🇸 USA
Prandin (US)
🧮 Dose calculator
Type 2 diabetes mellitus · Regimen source: FDA Repaglinide · 2.1
- • Within 30 min before meals; skip the dose if the meal is skipped. Double weekly up to 4 mg with each meal. With cyclosporine max 6 mg/day. FDA Repaglinide · 2.1FDA Repaglinide · 7
Enter age (weight is optional for this regimen).
🛡️ Safety & information
Contraindications
- ⛔ Concomitant gemfibrozil; hypersensitivity. FDA Repaglinide · 4
Formulations
- 0.5 mg tablet — tablet 🇺🇸 USA FDA Repaglinide · How Supplied
- 1 mg tablet — tablet 🇺🇸 USA FDA Repaglinide · How Supplied
- 2 mg tablet — tablet 🇺🇸 USA FDA Repaglinide · How Supplied
👥 Special populations
- 🤰 PregnancyUse with caution
Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Repaglinide · 8.1
“Risk Summary Limited available data from case reports and case series with repaglinide tablets use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes.”
- 🤱 BreastfeedingUse with caution
Label: use with caution while breastfeeding; see the label text. FDA Repaglinide · 8.2
“Risk Summary There are no data on the presence of repaglinide in human milk, the effects on the breastfeeding infant, or the effects on milk production.”
- 👶 ChildrenUse with caution
The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Repaglinide · 8.4
“Safety and effectiveness have not been established in pediatric patients.”
- 👴 Older adultsUse with caution
Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Repaglinide · 8.5
“In clinical studies of 24 weeks or greater duration, 415 patients were over 65 years of age and no patients were greater than 75 years of age.”
- ⚥ Females & males of reproductive potentialNo data
The source for this drug has no section for this group.
🔗 Reference links
- FDA (approval record)ANDA207209
- DailyMed (FDA label)FDA Repaglinide
- MedlinePlus (NIH)Repaglinide
- WHO ATC/DDDA10BX02
- Darooyab (Iran)Repaglinide
🇮🇷 Registered in Iran Darooyab · G-648/Repaglinide
Dosage forms with Iranian generic codes, per Darooyab.
- 21635 · REPAGLINIDE 0.5MG CAP · کپسول رپاگلیناید ۰٫۵ میلیگرم
- 04903 · REPAGLINIDE 0.5MG TAB · قرص رپاگلیناید ۰٫۵ میلیگرم
- 21636 · REPAGLINIDE 1MG CAP · کپسول رپاگلیناید ۱ میلیگرم
- 04904 · REPAGLINIDE 1MG TAB · قرص رپاگلیناید ۱ میلیگرم
- 21637 · REPAGLINIDE 2MG CAP · کپسول رپاگلیناید ۲ میلیگرم
- 04905 · REPAGLINIDE 2MG TAB · قرص رپاگلیناید ۲ میلیگرم
📚 Reference status for this drug
Shows which sources have references recorded for this drug and which do not.
- FDA label (DailyMed)✅ PresentFDA Repaglinide · How SuppliedFDA Repaglinide · 2.1FDA Repaglinide · 7FDA Repaglinide · 4FDA Repaglinide · 8.1FDA Repaglinide · 8.2FDA Repaglinide · 8.4FDA Repaglinide · 8.5FDA Repaglinide · SPL approval / marketing category
- UK SmPC (eMC / MHRA)❌ Not present
- Published guideline❌ Not present
- Licensed reference (medical school)❌ Not present
- Iranian leaflet (IFDA)❌ Not present
- Pharmacy website (secondary, unreliable)✅ PresentDarooyab · G-648/Repaglinide
- Clinical review⚠ Unverified